ad image

Company Info

DIANT Pharma

Drug Discovery & Development / Equipment

Overview

DIANT Pharma was founded in 2019 and has developed a continuous processing technology applicable for nanoparticle drug products and vaccines. We strive to offer a technology that is robust and reliable from R&D to manufacturing; over a product’s lifespan.

Our proprietary continuous manufacturing system for nanoparticles has a wide array of applications within the pharmaceutical space.

We are always looking for partners to broaden the use of our technology. Please contact us.

Contributions

Contributors

Contributions

7 Contributions1 / 1

Lipid Nanoparticles

Feasibility Studies and cGMP Design Supporting Continuous Lipid Nanoparticle Manufacturing

Jim Ziogas

DIANT Pharma

PAO-05-24-CL-03May 30, 2024

mRNA–LNP Manufacturing

The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles

Antonio Costa, Ph.D.; William Pasek

DIANT Pharma

PAO-03-24-CL-08Mar 18, 2024

Lipid Nanoparticles

Facilitating Development and Scale-Up of Nanoparticle Drug Products with an End-to-End Adaptable Manufacturing Platform

Antonio Costa, Ph.D.

DIANT Pharma

PAO-10-23-CL-03Nov 01, 2023

Continuous Processing

US Food and Drug Administration (FDA) Purchase the LiFT System from DIANT® Pharma INC.

DIANT Pharma

PR-M07-23-03Jul 31, 2023

Lipid Nanoparticles

Facilitating Lipid Nanoparticle Production with a Unique Continuous Manufacturing Solution

Antonio Costa, Ph.D.; William Pasek

DIANT Pharma

PAO-04-23-CL-05May 06, 2023

Lipid Nanoparticles

Lipid Nanoparticles: Transforming the Nanomedicines Market

Antonio Costa, Ph.D.

DIANT Pharma

PAO-02-23-CL-01Feb 07, 2023

Nanoparticles

Innovating Nanoparticles for Pharmaceutical Applications

DIANT Pharma

PAO-02-22-R250-18Feb 24, 2022

1 / 1

3 Contributors1 / 1

Antonio Costa, Ph.D.

Chief Executive Officer and Founder

William Pasek

Chief Commercial Officer

Jim Ziogas

Sales Engineer

1 / 1